Introduction
============

Because high-intensity chemotherapy and immunosuppressive therapy have been commonly used in patients with hematologic malignancy, the incidence of invasive fungal infection has increased. Primary antifungal prophylaxis has reduced the incidence of invasive fungal infection and has improved the survival rate and prognosis in patients with prolonged neutropenia after chemotherapy and stem cell transplantation \[[@B1]\]. While primary antifungal prophylaxis has been generally used, the incidence of non-Aspergillus mold or non-Candida yeast infection has steadily increased that has not been observed before \[[@B2][@B3]\].

*Trichosporon asahii* is a urease-positive, non-encapsulated basidiomycetous yeast. In recent years, *T. asahii* has been reported in several cases as an important life-threatening opportunistic systemic pathogen with reduced susceptibility to antifungal therapy in immunocompromised and immunocompetent patients who were receiving broad-spectrum antibiotics for a long period, in diabetic patients, or in heavy alcoholics, and even in healthy individuals \[[@B4][@B5]\].

Here, we present a case of catheter-related *T. asahii* bloodstream infection with multiple septic skin nodules during the neutropenic period after allogeneic stem cell transplantation (SCT) that was successful treated with voriconazole. This study was approved by the institutional review board of Seoul St. Mary's Hospital at the Catholic University of Korea, with a waiver of informed consent (subject no. KC13RISI0364).

Case report
===========

A 54-year-old woman was admitted for allogeneic SCT in March 2014. She was diagnosed as myelodysplastic syndrome 4 months before and was treated with steroid and methotrexate therapies for Crohn's disease. On admission, her vital signs were stable, and her physical examination findings were unremarkable. The myeloablative conditioning regimen was initiated. Ciprofloxacin (1,000 mg/day) and itraconazole suspension (10 mg/kg/day) were administered as prophylaxis, and isoniazid (300 mg/day) was administered for latent tuberculosis. On day 5 of SCT, the patient complained of Hickmann catheter exit site pain and showed redness and swelling without fever ([Fig. 1](#F1){ref-type="fig"}). Her blood cell count indicated neutropenia (absolute neutrophil count, 0.69 × 10^9^/L), and her C-reactive protein (CRP) level was 4.13 mg/dL. Blood culture from the Hickmann catheter and peripheral line was performed, and teicoplanin (400 mg intravenous loading three times and then 400 mg once a day) was administered. The Hickmann catheter was removed, and a catheter tip culture was also performed. On day 6 of SCT, neutropenic fever developed, with increasing body temperature of up to 38.4°C. Her blood pressure and pulse rate were 110/70 mm Hg and 108 beats/min, respectively. No definite abnormal results were observe on her chest radiograph, blood chemistry tests, and urinalysis. Empirical antibiotics, 4 g/day cefepime and 400 mg/day isepamicin were administered, and itraconazole was substituted with 50 mg/day micafungin because of intolerance. On day 7 of SCT (33 hours after entering the automated blood culture system), blood culture from the Hickmann catheter was reported to be positive, and the Gram stain finding revealed a yeast-like organism. We decided to continue the micafungin therapy but increased the dose to 100 mg for suspicion of candidemia.

![Catheter exit site](ic-50-138-g001){#F1}

On day 8 of SCT, the fever persisted, and multiple skin nodules and erythema of various sizes on both legs and arms appeared ([Fig. 2](#F2){ref-type="fig"}). The antibiotic agents were changed to meropenem (3 g/day). The results of the galactomannan and cryptococcal antigen tests were both repetitively negative. After 5 days of incubation (day 10 of SCT), white to cream-colored colonies (\>15 colony-forming units) with raised surfaces on potato dextrose agar plates were observed ([Fig. 3](#F3){ref-type="fig"}). On day 10 of SCT, blood culture from the Hickmann catheter and catheter tip culture finally yielded *T. asahii*, but nothing from the peripheral line. Intravenous voriconazole was administered as treatment for *T. asahii* fungemia (6 mg/kg iv twice daily for loading for 1 day and then 4 mg/kg iv twice a day for maintenance) instead of micafungin.

![Skin lesions on both legs with multiple erythematous nodules](ic-50-138-g002){#F2}

![(A) After 2 days of incubation. (B) After 5 days of incubation, white to cream-colored colonies with raised surfaces appeared on potato dextrose agar plates.](ic-50-138-g003){#F3}

![Microscopic morphology of *T. asahii*: septate hyphae and pseudohyphae with arthroconidia (Gram staining, ×1000)](ic-50-138-g004){#F4}

*In vitro* studies of susceptibility to amphotericin B, fluconazole, itraconazole, caspofungin, and voriconazole were performed by using the microbroth dilution technique and the guidelines of the National Committee for Clinical Laboratory Standards \[[@B6]\]. The minimal inhibitory concentrations (MICs) were as follows: amphotericin B, 1 mg/mL; fluconazole, 8 mg/mL; itraconazole, 16 μg/mL; caspofungin, 16 μg/ml; and voriconazole, 0.5 μg/mL.

On day 14 of SCT (*i.e.*, day 5 of voriconazole therapy), the neutrophil count recovered (absolute neutrophil count, 1.25 × 10^9^/L), but follow-up blood culture persistently showed *T. asahii* fungemia, and the CRP level increased up to 33.1 mg/dL. On day 20 of SCT (day 12 of voriconazole therapy), fungemia disappeared with defervescence, and septic skin emboli were cleared. Intravenous voriconazole was changed to tablet form and continued for 30 days after negative conversion of fungemia. She is still alive without any complication 16 months after SCT.

Discussion
==========

*Trichosporon* species are distributed in external environments, such as soil, wood, and air, and they are a part of the normal flora of the human skin (especially the peri-genital area), respiratory tract, and gastrointestinal tracts \[[@B7]\]. All pathogenic members of the genus *Trichosporon* were once regarded as a single species, *T. beigelii* \[[@B7]\]. However, the genus has undergone several reclassifications, and more recently, 50 species have been described, of which 16 species have been associated with human infections \[[@B7][@B8]\]. In most cases, *T. asahii* (74%) has emerged as an important life-threatening opportunistic systemic pathogen because of the increased use of cytotoxic or immunosuppressant agents. The clinical manifestations of *Trichosporon* infection represent various ranges from localized form or disseminated in multiple organs, particularly in immunocompromised patients \[[@B4][@B9][@B10]\]. The infection most commonly presents as fungemia (75%), and approximately 50% of cases are associated with metastatic skin lesions such as papular-purpuric, nodular, vesicular, or pustular lesions \[[@B10]\].

The diagnosis of invasive *Trichosporon* infection is based on microscopy in wet mount or tissue biopsy specimen and culture \[[@B7]\]. The microscopic morphology of *T. asahii* shows septated hyphae, pseudohyphae, and blastoconidia, with cylinder-shaped arthroconidia \[[@B7]\]. Colonies on solid media are white with raised farinose surfaces, but *T. asahii* on CHROM agar forms characteristic dirty-green colonies. However, tissue biopsy may be difficult for patients with hematologic malignancy because of thrombocytopenia and culture-based phenotypic methods are insensitive, with low positivity rates. Non-culture-based methods for diagnosis of invasive fungal infection are gradually needed to overcome the limitations of test insensitivity and delayed results \[[@B7]\]. A recent report of 33 cases of *Trichosporon* fungemia in Japan indicated that (1--3)-β-D-glucan levels may have serious limitations for the early detection of invasive trichosporonosis unlike candidiasis and aspergillosis \[[@B11][@B12]\]. *Trichosporon* species share antigens with *Cryptococcus* and *Aspergillus*. Many previous reports have demonstrated a cross reaction for the cryptococcal and galactomannan antigens \[[@B8][@B11]\]. Therefore, dual positivity in these tests may be interpreted as an indicator of invasive trichosporonosis, but the sensitivity and specificity of these tests have not been defined \[[@B8]\]. More recently, molecular tests, including polymerase chain reaction-based methods, flow cytometry assays, and proteomics, are being developed \[[@B7]\].

Definite treatment guidelines for invasive *T. asahii* infections are yet to be established. In previous cases, *Trichosporon* species are resistant to flucytosine or echinocandins and show various susceptibilities in vitro and limited activity to amphotericin B *in vivo* \[[@B4][@B13]\]. However, recent study results suggest that azoles are superior to other antifungal drug classes in prophylaxis and treatment for *Trichosporon* infections with low MICs \[[@B10][@B12]\]. On the basis of a head-to-head comparison of five triazoles, voriconazole showed the best therapeutic effect in terms of *in vitro* and *in vivo* activities and good results for treating disseminated *T. asahii* infection \[[@B14]\]. The combination of voriconazole with amphotericin B or echinocandin appears to have some synergistic antifungal effects in some reports \[[@B15]\].

We describe the case of a breakthrough catheter-related *T. asahii* bloodstream infection during itraconazole prophylaxis. This is the second reported case of *T. asahii* bloodstream infection case in Korea, after subsequent reclassification \[[@B16]\]. Although the patient received triazole as prophylaxis, we treated her with voriconazole single as primary therapy, which showed successful treatment results without any complications. As primary antifungal prophylaxis is widely used, the invasive fungal infection epidemiology has changed steadily \[[@B2]\]. Moreover, in the past, many antifungal agents used for prophylactic purposes were prescribed with a treatment aim; thus, physicians should consider antifungal resistance and treatment failure due to prior exposure. Therefore, physicians should be concerned about voriconazole treatment failure in breakthrough *T. asahii* fungemia during triazole prophylaxis even if this is known to be the best treatment agent for *T. asahii* infection.

To identify other cases of breakthrough *T. asahii* fungemia in patients with hematologic malignancy with antifungal use, we searched the Medline database (National Library of Medicine, Bethesda, MD, USA) and found reports of 13 cases \[[@B4][@B5][@B9][@B13][@B14][@B15][@B17][@B18][@B19][@B20]\] ([Table 1](#T1){ref-type="table"}). Breakthrough trichosporonosis has been reported during the administration of various antifungal agents except voriconazole. Treatment outcomes varied. However, voriconazole-containing regimens seemed to have better treatment results, even if the patients received prophylaxis with triazole \[[@B5][@B9]\]. MICs of antifungal agents were observed in 8 patients. All the strains isolated from the 8 patients examined were highly resistant to echinocandin. The MICs for amphotericin B deoxycholate and fluconazole varied, whereas the MICs for itraconazole and voriconazole were relatively low. Resistance to one triazole does not seem to imply resistance against the whole class of drugs. However, only few data demonstrate the relationship between prophylactic antifungal use and drug resistance; thus, future investigations in larger patient cohorts are needed.

###### Summary of cases of breakthrough *Trichosporon asahii* fungemia in patients with hematologic disease who were receiving antifungal agents (including the present case)

![](ic-50-138-i001)

  Underlying disease         Predisposing condition   Site of infection   Previous antifungal Tx.   Definite Tx. of trichosporonosis   Outcome    AMB    FLC    ITC   VRC       CAF    MIF    Ref.
  -------------------------- ------------------------ ------------------- ------------------------- ---------------------------------- ---------- ------ ------ ----- --------- ------ ------ --------------
  Myelodysplastic syndrome   SCT                      Catheter            ITC                       VRC                                Survived   1      8      16    0.5       16            In this case
  AML                        CTx                      Primary fungemia    CAF                       L-AMB + VRC                        Expired    \>32   4      0.5   \>0.015   16            \[[@B4]\]
  AML                        CTx                      Primary fungemia    ITC                       VRC                                Survived   1      32     1     0.5              \>16   \[[@B5]\]
  Thalassemia                SCT                      Catheter            FLC                       VRC                                Survived   0.25   3            0.04      \>32          \[[@B9]\]
  AML                        CTx                      Catheter            FLC                       AMB + CAF                          Survived   0.06   \>64                                 \[[@B13]\]
  Hematologic malignancy     SCT                      Primary fungemia    MIF                       L-AMB                              Survived   S      S      S     S         R      R      \[[@B14]\]
  AML                        CTx                      Catheter            FLC                       L-AMB + CAF                        Survived                                               \[[@B15]\]
  AML                        CTx                      GI tract            PSC                       VRC + AMB                                                                                 \[[@B17]\]
  AML                        CTx                      Catheter            ITC                       AMB + FLC                          Survived                                               \[[@B18]\]
  Myelofibrosis              CTx                      Primary fungemia    MIF                       L-AMB                              Expired                                                \[[@B19]\]
  Myelodysplastic syndrome   CTx                      Catheter            MIF                       FLC                                Expired                                                \[[@B20]\]
  AML                        SCT                      Primary fungemia    MIF                       FLC                                Expired                                                \[[@B20]\]
  AML                        CTx                      Pneumonia           AMB + CAF                 VRC                                Expired    0.5    8      1                      16     \[[@B20]\]
  AML                        CTx                      Primary fungemia    MIF                       VRC                                Survived   1      32     1                      16     \[[@B20]\]

AMB, amphotericin B deoxycholate; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AML, acute myeloid leukemia; CAF, caspofungin; MIF, micafungin; SCT, stem cell transplantation; CTx, chemotherapy; L-AMB, liposomal amphotericin B; PSC, posaconazole.

Blank, not commented in the reference article.

Clinicians should be aware that cases of disseminated *Trichosporon* infections have been increasingly reported worldwide, and these infections may develop in immunocompromised patients, particularly those who have intravascular devices and develop symptoms and signs of a breakthrough infection while receiving primary antifungal prophylaxis. Further research should be performed to investigate *in vitro* and *in vivo* activities of antifungal drugs against *T. asahii*, resistance mechanisms, non-culture-based diagnostic methods, and more detailed treatment strategies, including combination therapy and treatment duration. Based on this case, we emphasize that early suspicion and diagnosis of breakthrough *T. asahii* infection are important in high-risk patients, even in those receiving antifungal agents, and can lead to proper therapeutic choice and improved prognosis.
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